Clinical Trial Site

Orlando, Florida 32825

3 studies enrolling now · 17 studies all time

What they study most

Acid Cholesteryl Ester Hydrolase Deficiency, Type 2, Acid Lipase Deficiency, Advanced Breast Cancer, Breast Cancer, Cholesterol Ester Storage Disease, Dravet Syndrome, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma, HIV Infections, Healthy, Hepatic Impairment, Hepatitis C

Studies at this site

• Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease — Recruiting now
• OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer — Recruiting now
• Lysosomal Acid Lipase (LAL) Deficiency Registry — Recruiting now
• Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution — Running, not enrolling
• Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) — Completed
• A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension — Completed
• Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) — Completed
• A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery — Completed
• A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM — Stopped early
• Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer — Completed
• Study of ALXN2050 in Participants With Renal Impairment — Completed
• Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants — Completed
• Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants — Completed
• Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation — Completed
• An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment — Completed
• Study of Danicopan in Participants With Hepatic Impairment — Completed
• Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction — Completed